RPRX

RoyaltyB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$58.80

+8.9% vs current

Most likely

Base case

55%

Probability

Target price

$46.34

-14.2% vs current

B-

Bear case

20%

Probability

Target price

$38.00

-29.6% vs current

AI sentiment snapshot

Latest data as of 2026-01-31

AI commentary

Market/consensus snippets show a mild positive tilt: multiple sources place the average 12-month target above the current anchor, indicating analyst upside (median ~46.34; mean ~43.45) [#SERP-1], [#SERP-7]. However coverage includes low-end estimates and at least one outlier low, producing a mixed tenor and highlighting distribution risk [#SERP-3]. Overall sentiment is cautiously constructive, contingent on royalty cash flow stability and acquisition execution.

RankAlpha Sentiment AI - 2026-01-31

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-30catalystFY/Quarterly results and guidance updateHigh impact

Company quarterly/FY results can reprice consensus and dividend/royalty guidance; assumed reporting window not explicit in sources so a conservative short-date is used. Assumed date: 2026-04-30 (conservative) [#SERP-5].

2026-06-30eventMajor portfolio acquisition or dispositionHigh impact

Large royalty acquisitions/dispositions materially change NAV and leverage; no firm public date available so pick window end and note assumption: assumed event end date 2026-06-30 (conservative estimate) [#SERP-1], [#SERP-3].

2027-01-31catalystAnalyst re-rating from updated consensus and macro/interest-rate tailwindsHigh impact

Analyst coverage and consensus 12-month targets can re-rate the stock over a longer window; assumed date (long horizon): 2027-01-31 (conservative 12-month horizon). Comparison/consensus fragments cited in sources [#SERP-1], [#SERP-7].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-31 • Updated nightlySource: Internal modelMethodology